Importer of Controlled Substances Application: Fisher Clinical Services, Inc., 60269 [2020-21083]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 186 / Thursday, September 24, 2020 / Notices
Dated: September 21, 2020.
Shelly L. Cox,
Rules Committee Staff.
Controlled substance
Tapentadol ................
[FR Doc. 2020–21115 Filed 9–23–20; 8:45 am]
BILLING CODE 2210–55–P
Drug
code
9780
Schedule
II
The company plans to import the
listed controlled substances for clinical
trials.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
William T. McDermott,
Assistant Administrator.
[Docket No. DEA–724]
[FR Doc. 2020–21083 Filed 9–23–20; 8:45 am]
BILLING CODE 4410–09–P
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Fisher Clinical Services, Inc.
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before October 26, 2020. Such
persons may also file a written request
for a hearing on the application on or
before October 26, 2020.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on July 31, 2020, Fisher
Clinical Services, Inc., 700A–C Nestle
Way, Breinigsville, Pennsylvania
18031–1522, applied to be registered as
an importer of the following basic
class(es) of controlled substance(s):
SUMMARY:
Controlled substance
Psilocybin .................
Methylphenidate .......
Levorphanol ..............
Noroxymorphone ......
VerDate Sep<11>2014
Drug
code
Schedule
7437
1724
9220
9668
17:00 Sep 23, 2020
I
II
II
II
Jkt 250001
DEPARTMENT OF JUSTICE
Notice of Lodging of Proposed
Consent Decree Under the
Comprehensive Environmental
Response, Compensation and Liability
Act (CERCLA)
On September 17, 2020, the United
States lodged a proposed Consent
Decree with the United States District
Court for the Western District of
Kentucky in the lawsuit entitled United
States v. Goodrich Corporation,
Westlake Vinyls, Inc., and PolyOne
Corporation, Civil Action No. 5:20–cv–
00154–TBR.
The proposed Consent Decree
resolves certain claims brought on
behalf of the United States
Environmental Protection Agency
(‘‘EPA’’) under Sections 106 and 107 of
CERCLA, 42 U.S.C. 9606, 9607, and
Section 7003 of the Resource
Conservation and Recovery Act, 42
U.S.C. 6973, against Goodrich
Corporation, Westlake Vinyls, Inc., and
PolyOne Corporation (collectively
‘‘Defendants’’) for costs incurred and to
be incurred at the B.F. Goodrich Site
(‘‘Site’’) located in Calvert City,
Marshall County, Kentucky. Under the
proposed Consent Decree, the
Defendants will implement the
Remedial Action for the Site selected in
EPA’s Record of Decision, issued in
September of 2018. Key elements of the
remedy include the installation of a
three-mile long sub-surface barrier wall
around the perimeter of the onshore
contamination; collection and treatment
of groundwater within the containment
area; recovery of non-aqueous phase
liquid (‘‘NAPL’’) from accessible
onshore areas; dredging of contaminated
sediments from the barge slip; closure of
two ponds; recovery of NAPL from
beneath the Tennessee River; and
treatment of the groundwater plume
beneath the river. The estimated cost of
the cleanup work to be performed by the
Defendants pursuant to the Consent
Decree is $97,000,000. Under the
Consent Decree the Defendants have
agreed to pay all of EPA’s costs incurred
PO 00000
Frm 00145
Fmt 4703
Sfmt 9990
60269
in overseeing the construction of the
Remedial Action.
The Settlement Agreement includes
certain covenants not to sue under
Sections 106 and 107 of CERCLA, 42
U.S.C. 9606, 9607, and Section 7003 of
RCRA, 42 U.S.C. 6973, with respect to
the Site. As provided by RCRA, a public
meeting will be held on the proposed
settlement if requested in writing by
fifteen (15) days after the publication
date of this notice. Requests for a public
meeting may be made by contacting the
EPA Remedial Project Manager, Brad
Jackson by email at Jackson.Brad@
epa.gov. If a public meeting is
requested, information about the date
and time of the meeting will be
published in the local newspaper, and
will be sent to persons on the EPA B.F.
Goodrich Superfund Site mailing list.
The publication of this notice opens
a period for public comment on the
Consent Decree. Comments should be
addressed to the Assistant Attorney
General, Environment and Natural
Resources Division, and should refer to
U.S. v. Goodrich, et al., D.J. Ref. No. 90–
11–3–12205. All comments must be
submitted no later than thirty (30) days
after the publication date of this notice.
Comments may be submitted either by
email or by mail:
To submit
comments:
Send them to:
By email .......
pubcomment-ees.enrd@
usdoj.gov.
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington, DC
20044–7611.
By mail .........
During the public comment period,
the Consent Decree may be examined
and downloaded at this Justice
Department website: https://
www.justice.gov/enrd/consent-decrees.
We will provide a paper copy of the
Consent Decree upon written request
and payment of reproduction costs.
Please mail your request and payment
to: Consent Decree Library, U.S. DOJ—
ENRD, P.O. Box 7611, Washington, DC
20044–7611.
Please enclose a check or money order
for $14 for a copy of the Consent Decree
without Exhibits or $133.75 for a copy
of the Consent Decree with Exhibits (25
cents per page reproduction cost)
payable to the United States Treasury.
Lori Jonas,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2020–21049 Filed 9–23–20; 8:45 am]
BILLING CODE 4410–15–P
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 85, Number 186 (Thursday, September 24, 2020)]
[Notices]
[Page 60269]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-21083]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-724]
Importer of Controlled Substances Application: Fisher Clinical
Services, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Fisher Clinical Services, Inc. has applied to be registered as
an importer of basic class(es) of controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before October 26,
2020. Such persons may also file a written request for a hearing on the
application on or before October 26, 2020.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on July 31, 2020, Fisher Clinical Services, Inc., 700A-C
Nestle Way, Breinigsville, Pennsylvania 18031-1522, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Psilocybin............................ 7437 I
Methylphenidate....................... 1724 II
Levorphanol........................... 9220 II
Noroxymorphone........................ 9668 II
Tapentadol............................ 9780 II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
clinical trials.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-21083 Filed 9-23-20; 8:45 am]
BILLING CODE 4410-09-P
